SNY's new drugs are gaining momentum, with Altuviiio, Ayvakit and Sarclisa poised to broaden growth beyond Dupixent.
TARRYTOWN, N.Y., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its third quarter 2026 financial and operating results on Friday,
Regeneron Pharmaceuticals has delivered a strong share price run over the past year, which puts a spotlight on whether the current US$801.82 level is still grounded in what the business earns today. W
Regeneron Pharmaceuticals (NASDAQ:REGN) executives highlighted continued growth across key marketed products, a broad late-stage pipeline and an ongoing focus on science-driven business development du
Regeneron Pharmaceuticals, Inc. (REGN) Bernstein Insights: Healthcare Leaders and Disruptors - 3rd Annual Healthcare Forum September 23, 2026 10:30 AM...
Veeva Systems (NYSE: VEEV) today announced a new top 20 biopharma commitment, adding to recent selections by Amgen, Biogen, Eli Lilly and Company, and Regeneron. With more than 190 live customers and
The past couple of years have been challenging for the company, but there is a light at the end of the tunnel.
Regeneron Pharmaceuticals (NASDAQ:REGN) has outperformed the market over the past 20 years by 12.55% on an annualized basis producing an average annual return of 21.73%. Currently, Regeneron Pharmaceu
View interactive chart, options flow, and AI analysis for REGN on Zorveq Finance.
Open REGN Chart & Analysis →